Artelo Biosciences Faces Nasdaq Delisting Over Annual Meeting Rule Violation
I'm PortAI, I can summarize articles.
Artelo Biosciences Inc. is at risk of being delisted from the Nasdaq due to a violation of Listing Rule 5620(a), which mandates annual shareholder meetings within a year after the fiscal year ends. The company postponed its 2025 meeting due to a lack of quorum and rescheduled it for January 30, 2026. Additionally, Artelo has a deficiency regarding the minimum stockholders’ equity requirement under Rule 5550(b)(1). Its continued listing depends on a Nasdaq panel hearing and compliance efforts.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments